<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630952</url>
  </required_header>
  <id_info>
    <org_study_id>KHB-1802</org_study_id>
    <nct_id>NCT03630952</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)</brief_title>
  <official_title>A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the efficacy and safety of two different&#xD;
      levels of conbercept intravitreal (IVT) injection as compared to the approved vascular&#xD;
      endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal&#xD;
      injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled,&#xD;
      randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to&#xD;
      receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The&#xD;
      trial includes a screening period of less than or equal to 14 days, followed by a treatment&#xD;
      period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    desired primary endpoint was not met&#xD;
  </why_stopped>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Actual">May 19, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects maintaining vision (i.e., losing &lt;15 ETDRS BCVA letters) from baseline to Week 36</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>To Assess Proportion of subjects maintaining vision (i.e., losing &lt;15 ETDRS BCVA letters) from baseline to Week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>To Assess Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>To Assess Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects maintaining vision (i.e. losing &lt;15 ETDRS BCVA letters) from baseline to Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>To Assess Proportion of subjects maintaining vision (i.e. losing &lt;15 ETDRS BCVA letters) from baseline to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in ETDRS BCVA letter score at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>To Assess Mean change from baseline in ETDRS BCVA letter score at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as measure of safety and tolerability</measure>
    <time_frame>Baseline to Week 96</time_frame>
    <description>To Assess Number of participants with adverse events as measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible</measure>
    <time_frame>Baseline to Week 96</time_frame>
    <description>To Assess Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible</measure>
    <time_frame>Baseline to Week 96</time_frame>
    <description>To Assess Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible</measure>
    <time_frame>Baseline to Week 96</time_frame>
    <description>To Assess Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1157</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>0.5 mg Conbercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg Conbercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5 mg Conbercept Intravitreal Injection</intervention_name>
    <description>Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
    <arm_group_label>0.5 mg Conbercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1.0 mg Conbercept Intravitreal Injection</intervention_name>
    <description>Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
    <arm_group_label>1.0 mg Conbercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.0 mg Aflibercept Intravitreal Injection</intervention_name>
    <description>Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 50 years of age at the Screening visit;&#xD;
&#xD;
          2. Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of&#xD;
             childbearing potential, must have a negative pregnancy test at the Screening visit;&#xD;
&#xD;
             o Women of childbearing potential must agree to use a highly effective method of&#xD;
             contraception throughout the study.&#xD;
&#xD;
          3. Have received no previous treatment for neovascular AMD, including laser&#xD;
             photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists&#xD;
             (treatment naïve) and;&#xD;
&#xD;
          4. Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD&#xD;
             (including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein&#xD;
             angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at&#xD;
             Screening;&#xD;
&#xD;
          5. Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening;&#xD;
&#xD;
          6. Are willing and able to sign the study written informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have had any prior ocular or systemic treatment (investigational or approved) or&#xD;
             surgery for the treatment of neovascular AMD in the study eye except dietary&#xD;
             supplements or vitamins;&#xD;
&#xD;
          2. Have participated as a subject in any interventional clinical trial within one month&#xD;
             (30 days) prior to Baseline visit;&#xD;
&#xD;
          3. Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or&#xD;
             blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2)&#xD;
             in the study eye at Screening;&#xD;
&#xD;
          4. Have any retinal pigment epithelial tears or rips in the study eye at Screening or&#xD;
             upon examination at Baseline;&#xD;
&#xD;
          5. Have any vitreous hemorrhage in the study eye upon examination at Baseline or history&#xD;
             of vitreous hemorrhage within eight weeks prior to Screening;&#xD;
&#xD;
          6. Have any other cause of CNV;&#xD;
&#xD;
          7. Have had prior pars plana vitrectomy in the study eye;&#xD;
&#xD;
          8. Have presence of a full thickness macular hole at Screening or upon examination at&#xD;
             Baseline or a history of a full thickness macular hole in the study eye;&#xD;
&#xD;
          9. Have prior trabeculectomy or other filtration surgery in the study eye;&#xD;
&#xD;
         10. Have uncontrolled glaucoma;&#xD;
&#xD;
         11. Have active intraocular inflammation in either eye at Screening or upon examination at&#xD;
             Baseline or a history of uveitis in either eye;&#xD;
&#xD;
         12. Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as&#xD;
             a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.&#xD;
&#xD;
         13. Significant media opacities, including cataract, in the study eye that, in the opinion&#xD;
             of the Investigator, could require either medical or surgical intervention during the&#xD;
             study period;&#xD;
&#xD;
         14. Have any use of long acting intraocular steroids, including implants, within six&#xD;
             months prior to Day 1, Baseline;&#xD;
&#xD;
         15. Have any known allergy to povidone iodine or known serious allergy to the fluorescein&#xD;
             sodium for injection in angiography;&#xD;
&#xD;
         16. Any history of known contraindications indicated in the Food and Drug Administration&#xD;
             (FDA)-approved label for the active control;&#xD;
&#xD;
         17. If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Cheng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chengdu Kanghong Biotechnology Co.,Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Waterford</city>
        <state>Connecticut</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1517</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300384</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Sonderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Saint-Cyr sur Loire</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <state>Ha'Darom</state>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Poriyya</city>
        <zip>1520800</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Zrifin</city>
        <zip>7030000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Negrar</city>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1009</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Trenčín</city>
        <zip>91171</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>010 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Žilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Westcliff on Sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Gorleston-on-Sea</city>
        <state>Norfolk</state>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Canterbury</city>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Gorleston-On-Sea</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW1 5QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanghong Investigative Site</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

